Macrophage Activation Syndrome
EULAR, ACR: Likely HLH/MAS should be met with immunomodulation while diagnosis continues
Patients with likely hemophagocytic lymphohistiocytosis or macrophage activation syndrome should begin immunomodulation while the diagnostic investigation continues, according to new EULAR/American College of Rheumatology guidelines.
ACR: Continue daily monitoring in children with Kawasaki disease who have resolved fevers
PHILADELPHIA — In children with acute Kawasaki disease where fever symptoms have resolved, continued daily monitoring for 1 to 2 weeks is strongly recommended, according to new guidelines released during ACR Convergence 2022.
‘Can we do any better?’: Biomarkers, more data needed to reduce cytokine storm mortality
A more nuanced understanding of COVID-19-related cytokine storm syndrome may hold the key to minimizing fatalities, noted a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.
EULAR: Treat suspected cytokine storm syndromes in children with ‘urgency’
Clinicians are encouraged to investigate and treat suspected macrophage activation syndrome and hemophagocytic lymphohistiocytosis in children with “urgency,” according to a speaker at the EULAR 2021 Congress.
Serum biomarkers 'clearly separate' COVID-19 from classic cytokine storm syndromes
Increased interleukin‐1Ra and IL‐8 serum levels, and other biomarker profiles, “clearly separate” COVID-19 from macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis, according to data published in Arthritis & Rheumatology.
MIS-C mystery persists even as rheumatologists' arsenal proves key to treatment
As physicians around the world scrambled throughout early 2020 to respond to the exploding COVID-19 pandemic, the one promising development appeared to be that children were at relatively low risk compared with adults.
IL-1 inhibitors linked to ‘significant reduction’ in COVID-19 mortality
Interleukin-1 inhibitors are associated with a “significant reduction” in mortality among patients hospitalized with COVID-19, respiratory insufficiency and hyperinflammation, according to data published in The Lancet Rheumatology.
Systemic JIA subset linked to IL-18 may be at increased risk for cytokine storm
A subset of patients with systemic juvenile idiopathic arthritis with elevated interleukin-18 markers could face “increased risk” for macrophage activation syndrome, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.
IL-1, IL-6 blockade 'transformative' in sJIA, adult-onset Still’s disease
Advances in understanding of systemic juvenile idiopathic arthritis and adult-onset Still’s disease have elucidated the impact of biologic therapies on these conditions, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.
Ruling out mimics for systemic onset JIA often requires 'extensive workup'
A quotidian fever lasting at least 2 weeks is one of the hallmarks of systemic onset juvenile idiopathic arthritis, according to a presenter at the 2020 Rheumatology Nurses Society Annual Conference.